{
    "id": "361ecb56-1275-7f2d-e063-6294a90ac485",
    "indications": {
        "text": "guanfacine extended-release tablets indicated treatment attention deficit hyperactivity disorder ( adhd ) monotherapy adjunctive therapy stimulant medications [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "attention deficit hyperactivity disorder (DOID:1094)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1094"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended dose : 1 mg 7 mg ( 0.05 0.12 mg/kg target weight based dose range ) daily morning evening based response tolerability ( 2.2 ) . begin dose 1 mg daily adjust increments 1 mg/week ( 2.2 ) . crush , chew break tablets swallowing ( 2.1 ) . administer high-fat meals , increased exposure ( 2.1 ) . substitute immediate-release guanfacine tablets mg-per-mg basis , differing pharmacokinetic profiles ( 2.3 ) . switching immediate-release guanfacine , discontinue treatment titrate guanfacine extended-release tablets directed ( 2.3 ) . discontinuing , taper dose decrements 1 mg every 3 7 days avoid rebound hypertension ( 2.5 ) .",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "guanfacine extended-release tablets , usp 2 mg white off-white , oval shaped , biconvex tablets , engraved \u201c apo \u201d one side , \u201c gua 2 \u201d side . supplied follows : ndc : 70518-4266-00 ndc : 70518-4266-01 packaging : 100 1 box packaging : 1 1 pouch storage - store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect moisture . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "guanfacine extended-release tablets contraindicated patients history hypersensitivity reaction guanfacine extended-release tablets inactive ingredients , products containing guanfacine . rash pruritus reported .",
    "ingredients": [
        {
            "name": "HYPROMELLOSE 2208 (15000 MPA.S)",
            "code": "Z78RG6M2N2",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "FUMARIC ACID",
            "code": "88XHZ13131",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_18012"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "GUANFACINE HYDROCHLORIDE",
            "code": "PML56A160O",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5559"
        }
    ],
    "organization": "REMEDYREPACK INC.",
    "name": "Guanfacine extended-release",
    "effectiveTime": "20250527",
    "indications_original": "Guanfacine extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications\n \n  [see\n  \n   Clinical Studies (14)]\n \n  .",
    "contraindications_original": "Recommended dose: 1 mg to 7 mg (0.05 to 0.12 mg/kg target weight based dose range) once daily in the morning or evening based on clinical response and tolerability ( 2.2 ). Begin at a dose of 1 mg once daily and adjust in increments of no more than 1 mg/week ( 2.2 ). Do not crush, chew or break tablets before swallowing ( 2.1 ). Do not administer with high-fat meals, because of increased exposure ( 2.1 ). Do not substitute for immediate-release guanfacine tablets on a mg-per-mg basis, because of differing pharmacokinetic profiles ( 2.3 ). If switching from immediate-release guanfacine, discontinue that treatment and titrate with guanfacine extended-release tablets as directed ( 2.3 ). When discontinuing, taper the dose in decrements of no more than 1 mg every 3 to 7 days to avoid rebound hypertension ( 2.5 ).",
    "warningsAndPrecautions_original": "Guanfacine extended-release tablets, USP 2 mg are white to off-white, oval shaped, biconvex tablets, engraved \u201cAPO\u201d on one side, \u201cGUA 2\u201d on the other side. They are supplied as follows:\n                  NDC: 70518-4266-00\n                  NDC: 70518-4266-01\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  Storage - Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted from 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].\n                  Protect from moisture.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Guanfacine extended-release tablets are contraindicated in patients with a history of a hypersensitivity reaction to guanfacine extended-release tablets or its inactive ingredients, or other products containing guanfacine.\u00a0Rash and pruritus have been reported.",
    "drug": [
        {
            "name": "Guanfacine extended-release",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5558"
        }
    ]
}